Neumora Therapeutics Faces Key Catalyst With Upcoming Navacaprant Depression Data

Neumora Therapeutics (NASDAQ:NMRA) is preparing for a major catalyst with top-line results from two late-stage trials of its experimental depression treatment, navacaprant. The combined data from the KOASTAL-2 and KOASTAL-3 studies are expected in Q2 2026 after enrolling over 400 patients each by early 2026.

By Habib Ur Rehman Wed, June 17, 2026 at 6:17 PM GMT+3 2 min read · Yahoo Finance · June 17, 2026, 15:17 UTC

Tickers: $NMRA

Topics: biopharma pipeline depression treatment navacaprant phase trials

Read the full article at Yahoo Finance

More World news

Mercury Insurance Issues Safety Guidelines for Portable Generator Use During Power Outages PR Newswire · November 12, 2026, 14:06 UTC
Paratus Appoints New Senior Leadership to Drive Expansion into Asset-Backed Optimisation PR Newswire · November 12, 2026, 14:03 UTC
Transamerica Partners with Congruent Solutions to Modernize Retirement Plan Payroll Administration PR Newswire · November 12, 2026, 14:00 UTC
Kindo Raises $57.6 Million Total to Scale Enterprise AI Agent Management Platform PR Newswire · November 12, 2026, 14:00 UTC
Texans Credit Union Introduces Cash Back Checking and Ignite Youth Banking Suite PR Newswire · November 12, 2026, 14:03 UTC
Apple Announces Preorders for Select Smart Home Collection Accessories The Verge · November 12, 2026, 14:00 UTC
SolaREIT Surpasses $8.5 Billion Milestone in Clean Energy Land Financing PR Newswire · November 12, 2026, 14:00 UTC
Avalara Launches Native 1099 E-Filing Integration for Workday Financial Management PR Newswire · November 12, 2026, 14:00 UTC
Rocket Companies Appoints Datadog COO Adam Blitzer to Board of Directors PR Newswire · November 12, 2026, 14:00 UTC
ALKEME Insurance Announces 'ALKEME Bowl' Sponsorship of Arizona vs. Utah College Football Matchup PR Newswire · November 12, 2026, 14:00 UTC